DMAC (DiaMedica Therapeutics) Land And Improvements: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DMAC DiaMedica Therapeutics Inc DMAC
32 GF Score
Price $6.53
! 1 Warning Sign
View Full Analysis

What is DiaMedica Therapeutics Land And Improvements?

DiaMedica Therapeutics DMAC +3.14% 32 Land And Improvements is $0.00 Mil as of Mar. 2026. GuruFocus rates DMAC with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

DiaMedica Therapeutics's land and improvements for the quarter that ended in Mar. 2026 was $0.00 Mil.

DiaMedica Therapeutics Land And Improvements Historical Data

* Premium members only.

The historical data trend for DiaMedica Therapeutics's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DiaMedica Therapeutics Land And Improvements Chart

DiaMedica Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Land And Improvements
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

DiaMedica Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Land And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
DMAC
32GF Score
DiaMedica Therapeutics Inc DMAC
Land And Improvements is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DiaMedica Therapeutics Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Frequently Asked Questions Learn more about Land And Improvements →
What does a Land And Improvements of $0.00 Mil mean?
DiaMedica Therapeutics (DMAC) has a Land And Improvements of $0.00 Mil as of Mar. 2026. Land and improvements records the total value of a company's land and improvements to it. View historical data on DiaMedica Therapeutics and its competitors.
Is DiaMedica Therapeutics' Land And Improvements too high?
DiaMedica Therapeutics' current Land And Improvements is $0.00 Mil. Overall, DiaMedica Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does DiaMedica Therapeutics' Land And Improvements compare to XFOR and IKT?
DiaMedica Therapeutics' Land And Improvements of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Land And Improvements for a Biotechnology company?
A good Land And Improvements depends on the Biotechnology industry context. However, Land And Improvements should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Land And Improvements mean?
A high Land And Improvements can signal that a stock is expensive relative to its fundamentals. Land and improvements records the total value of a company's land and improvements to it. View historical data on DiaMedica Therapeutics and its competitors. DiaMedica Therapeutics's current Land And Improvements is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DiaMedica Therapeutics stock overvalued right now?
DiaMedica Therapeutics (DMAC) has a current Land And Improvements of $0.00 Mil. The current Land And Improvements is $0.00 Mil. DiaMedica Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Land And Improvements calculated?
Land And Improvements is calculated from a company's financial statements. For DiaMedica Therapeutics (DMAC), the current Land And Improvements is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DiaMedica Therapeutics Business Description

Address 301 Carlson Parkway, Suite 210, Minneapolis, MN, USA, 55305
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
32GF Score

Get the complete analysis for DMAC

Land And Improvements is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.53
Price